Preimplantation Genetic Testing for Monogenic disorders — from familial mutation to unaffected embryo transfer
Unlike PGT-A (aneuploidy screening), which uses a generic chromosome-counting assay applicable to any patient, PGT-M requires a bespoke test built around one specific family's pathogenic variant. This pre-cycle workup is the single longest step in the PGT-M pathway and must be completed before egg retrieval begins.
Before an IVF cycle can be linked to genetic testing, the exact disease-causing variant segregating in the family must already be known from prior diagnostic or carrier testing — PGT-M is a confirmatory, targeted test, not a discovery test. Common scenarios include:
• Autosomal recessive carrier couples: both partners carry one pathogenic allele in the same gene (e.g. CFTR for cystic fibrosis, HBB for sickle cell disease / beta-thalassemia) • Autosomal dominant at-risk parent: one partner carries a dominant pathogenic variant (e.g. HTT CAG-repeat expansion in Huntington's disease, BRCA1/2 for hereditary breast/ovarian cancer) • X-linked conditions: the mother is a carrier of an X-linked pathogenic variant (e.g. DMD for Duchenne muscular dystrophy)
A blood or saliva sample from both partners — and, when available, an affected or carrier relative — is sequenced to confirm the precise variant coordinates (chromosome position, reference/alternate allele) that the custom panel must target.
A clinical genetics laboratory designs primers that amplify the mutation site directly, plus a panel of single nucleotide polymorphisms (SNPs) flanking the gene on both sides. These flanking SNPs are chosen because they are highly heterozygous (informative) in this specific family and tightly linked to the disease locus (low recombination distance).
The panel is validated on parental DNA and, when available, on DNA from a known-affected or known-unaffected relative, to confirm which SNP alleles travel together with the pathogenic variant on each parental chromosome — establishing each parent's "risk haplotype" versus "safe haplotype".
Only after this validation is complete is the panel cleared for use on single-cell (or few-cell) embryo biopsy DNA, where the amount of starting material is far too small to tolerate an unvalidated assay.
Because custom design and validation take 4–8 weeks, couples are strongly advised to start the PGT-M workup well before their planned IVF stimulation cycle — starting it late is the most common cause of treatment delay in PGT-M care pathways.
Testing only the single mutated base directly in a biopsy of just 5-10 cells is technically risky: with such a small amount of template DNA, PCR can occasionally fail to amplify one of the two parental alleles at all — a phenomenon called allele dropout (ADO). If ADO strikes the informative test, a carrier embryo could be miscalled as affected, or an affected embryo miscalled as unaffected.
This is why modern PGT-M is never based on the mutation site alone. The flanking SNP haplotype acts as an independent, redundant confirmation: even if the direct mutation assay drops out in one cell, the surrounding linked markers still reveal which parental chromosome (risk or safe) was inherited. Building this redundancy into the panel design at the outset is what allows the assay to be trusted on trace amounts of embryonic DNA.
Once eggs are retrieved and fertilized by IVF/ICSI, embryos are cultured to the blastocyst stage (day 5-6), when they contain 100-300 cells organized into two distinct lineages. Biopsying the correct lineage, and amplifying the tiny amount of resulting DNA, is a delicate technical bridge between embryology and molecular genetics.
By day 5-6 of development, the embryo has formed a blastocyst: a fluid-filled cavity (blastocoel) surrounded by an outer ring of cells (trophectoderm, TE — which will form the placenta and extra-embryonic tissue) and an inner cluster of cells (inner cell mass, ICM — which will form the fetus itself).
Biopsying trophectoderm cells rather than ICM cells is a deliberate safety choice: because TE cells are fated to become placenta, not fetus, removing several of them carries no meaningful risk to the developing fetus, while still being genetically representative of the embryo in the vast majority of cases.
Under high-magnification microscopy, an embryologist uses a laser pulse to gently open the zona pellucida (the embryo's outer shell) and a fine glass pipette to aspirate 5-10 herniating trophectoderm cells, which are then mechanically or laser-assisted detached from the embryo. The biopsy typically takes only a few minutes per embryo.
Immediately after biopsy, the embryo is vitrified (ultra-rapid cryopreservation) and stored while the biopsy sample is sent for genetic analysis — this is the standard "freeze-all" PGT workflow, since results take days, far longer than the embryo could safely wait in culture.
A biopsy of 5-10 cells contains only about 30-60 picograms of genomic DNA — far too little for direct PCR-based mutation and SNP panel testing. Whole genome amplification methods (multiple displacement amplification, MDA; or multiple annealing and looping-based amplification cycles, MALBAC) are used to non-specifically amplify this trace DNA more than a million-fold, producing enough material for dozens of downstream PCR reactions.
WGA introduces its own technical challenge: amplification bias means some genomic regions amplify more efficiently than others, which is one of the root causes of allele dropout at specific loci — reinforcing why the linked-SNP haplotyping strategy (rather than single-site genotyping) is essential for reliable diagnosis.
A single trophectoderm cell contains roughly 6 picograms of DNA. WGA must reliably amplify this to micrograms of usable template — a factor of over one million — while preserving an accurate representation of both parental alleles at the mutation site and every flanking SNP.
With amplified DNA in hand, the custom panel designed in Stage 1 is run against each embryo's biopsy sample. The result is not a single yes/no readout at the mutation site, but a full haplotype block spanning the gene — the redundancy that makes PGT-M diagnosis robust against single-cell PCR failure.
A short PCR amplicon (typically 100-300 bp) spanning the exact pathogenic variant is amplified from the WGA product. Fluorescent probes, Sanger sequencing, or next-generation sequencing of the amplicon then reads out the base(s) present at the mutation coordinate, revealing whether the embryo carries zero, one, or two copies of the pathogenic allele at that position — in principle.
In parallel, the panel amplifies a set of highly informative SNPs positioned close to the disease gene on the same chromosome — typically 4-6 markers on each side, chosen during Stage 1 validation because they are tightly linked (very low recombination frequency, generally <1%) to the mutation and differ between the parents' risk and safe chromosomes.
Because these SNPs are physically close to the mutation, they are almost always inherited together with it as a block (a haplotype). By reading the SNP pattern, the lab can infer with high confidence which parental chromosome — risk or safe — each embryo inherited, even in cases where the direct mutation assay itself dropped out.
A diagnosis is only reported as reliable when the direct mutation result and the linked haplotype result agree; discordant results trigger re-analysis or an "inconclusive" call rather than a risky guess.
Allele dropout can affect any single PCR reaction on single-cell-level DNA, with reported rates around 5-10% per allele. Linked-marker haplotyping across many flanking SNPs reduces the chance that ADO goes undetected to well under 1%, since it is highly unlikely that ADO independently strikes both the direct assay and enough flanking markers to fully mask the true genotype.
Because SNP haplotyping relies on physical linkage rather than reading the mutation directly, it carries one intrinsic limitation: meiotic recombination (crossing-over) between the SNP marker and the disease gene can, rarely, separate them, causing a misleading haplotype call. Choosing markers very close to the gene (ideally <1 cM) keeps this recombination risk below roughly 1%, and using markers on both sides of the mutation allows a crossover on one side to be caught by markers on the other.
This is why validated multi-SNP panels — not single distant markers — are the modern clinical standard for PGT-M, combining the specificity of direct mutation detection with the robustness of flanking linkage analysis.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Cystic Fibrosis | CFTR — Autosomal recessive | Both parents carriers of pathogenic CFTR variant (e.g. ΔF508) | Most common recessive PGT-M indication |
| Sickle Cell Disease | HBB — Autosomal recessive | Both parents carriers of HbS or related beta-globin variant | Also screens for beta-thalassemia |
| Huntington's Disease | HTT — Autosomal dominant | One parent carries expanded CAG-repeat allele | Allows non-disclosure testing options |
| Hereditary Breast/Ovarian Cancer | BRCA1/BRCA2 — Autosomal dominant | One parent carries pathogenic BRCA variant | Reduces heritable cancer-risk transmission |
| Duchenne Muscular Dystrophy | DMD — X-linked recessive | Mother is carrier of pathogenic DMD variant | Sex plus haplotype jointly determine risk |
The haplotype call for each embryo is translated into a clinical genotype classification by comparing it against the expected segregation pattern for the family's specific mode of inheritance. The math is classical Mendelian genetics — but now resolved at the level of individual embryos rather than population statistics.
When both partners are carriers (heterozygous, Aa) for the same recessive pathogenic variant, classical Mendelian segregation predicts a 1:2:1 ratio among embryos: 25% homozygous unaffected (AA), 50% heterozygous carrier (Aa, phenotypically unaffected), and 25% homozygous affected (aa).
Only the 25% affected category poses disease risk to a future child; both the unaffected and carrier categories are suitable for transfer from a disease-avoidance standpoint, though many couples and clinics still prefer to prioritize non-carrier embryos when the cohort allows it, to avoid passing carrier status to the next generation.
When one parent carries a dominant pathogenic variant (heterozygous Aa) and the other is homozygous normal (aa), each embryo has a 50% chance of inheriting the pathogenic allele (Aa, affected) and a 50% chance of inheriting only normal alleles (aa, unaffected). There is no true "carrier" category for a fully penetrant dominant disorder — inheriting one copy is sufficient to confer risk.
For adult-onset dominant conditions such as Huntington's disease, some couples opt for "non-disclosure" or "exclusion" testing, which identifies at-risk embryos using linked markers without directly confirming the at-risk parent's own mutation status — preserving that parent's choice not to learn their own genetic risk.
When the mother is a carrier of an X-linked recessive pathogenic variant (XᴬXᵃ) and the father is unaffected (XᴬY), inheritance depends on both the inherited X and the embryo's sex chromosome complement: daughters have a 50% chance of being carriers (XᴬXᵃ) and 50% chance of being non-carriers (XᴬXᴬ); sons have a 50% chance of being affected (XᵃY) and 50% chance of being unaffected (XᴬY).
Across a full cohort this averages to roughly 25% unaffected daughters, 25% carrier daughters, 25% unaffected sons, and 25% affected sons — i.e. about 50% overall unaffected, 25% carrier, 25% affected. Embryonic sex is determined simultaneously by the same testing panel, since it is required to correctly interpret X-linked risk.
These are population-level probabilities describing the expected distribution across many embryos — the actual genotype of any single embryo is fixed at fertilization and is not a matter of chance once tested; PGT-M reveals which outcome already occurred rather than influencing it.
The final step translates molecular diagnosis into a clinical decision: ranking the tested embryo cohort and choosing the embryo (or embryos) least likely to result in an affected pregnancy, then proceeding to a frozen embryo transfer — completing the path from familial mutation to disease-free pregnancy.
Once every biopsied embryo has a genotype classification (unaffected / carrier / affected) and, when combined testing was performed, a chromosomal ploidy classification from PGT-A, the clinical team and patients rank the cohort. The typical priority order is:
1. Euploid + unaffected (no pathogenic allele, correct chromosome count) 2. Euploid + carrier (unaffected phenotype, chromosomally normal) 3. Mosaic or untested-ploidy + unaffected/carrier, considered case-by-case 4. Affected embryos and aneuploid embryos are generally excluded from transfer
Within the top tier, additional embryology grading (blastocyst morphology, expansion grade, ICM and TE quality) is used to select the single best embryo when several share the same genetic category.
PGT-M answers one question — did this embryo inherit the familial disease-causing variant? — but says nothing about whether the embryo has the correct number of chromosomes overall. Aneuploidy (an abnormal chromosome count) is a leading cause of implantation failure and miscarriage independent of any single-gene disorder, and its incidence rises steeply with maternal age.
Because the same trophectoderm biopsy and WGA product used for PGT-M can also be sequenced genome-wide for chromosome copy number, most clinics now run PGT-M and PGT-A from the same biopsy in a single combined workflow — maximizing information yield from what is clinically a limited and non-renewable biological sample.
Selecting an embryo that is both unaffected by the familial monogenic condition and chromosomally euploid does not guarantee a successful pregnancy, but it removes two of the most well-characterized, testable sources of pregnancy loss and inherited disease risk from the decision.
The vitrified, selected embryo is warmed and transferred to the uterus in a subsequent frozen embryo transfer (FET) cycle, timed to the recipient's endometrial preparation. Because PGT-M is performed on a small biopsy sample rather than the whole embryo, and because rare recombination or technical artifacts can theoretically still occur, professional guidelines recommend confirmatory prenatal diagnosis (chorionic villus sampling or amniocentesis) during any resulting pregnancy — PGT-M substantially reduces, but does not entirely eliminate, the residual risk of an affected pregnancy.
For couples with a known severe monogenic disease in the family, this combined pathway — familial variant mapping, custom panel design, biopsy, linked haplotyping, and informed embryo selection — offers a well-validated route to reducing transmission risk to the next generation while pursuing a genetically related pregnancy.